difference between glp and glp 1 The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 Receptor Agonists as Treatments

doi: 10.1056/NEJMoa1515920 71 XuW

Patients with impaired liver or kidney function need extra care, especially when using tirzepatide, which contains benzyl alcohol and may increase the risk of metabolic acidosis

Temporary bloating is not the same as weight gain

For example, the majority of RCTs are placebo-controlled and only a few RCTs are designed to provide head-to-head comparison between different active compounds, an aspect that is highly relevant from a clinical standpoint, since in the real-world physicians more often choose between one drug and another as compared to one drug or nothing

Care Companion J

Cardiovascular outcome trials CVOTs have emerged as a pivotal component of assessing the impact of GLP-1 receptor agonists on cardiovascular health ( GLP-1 receptor agonists have demonstrated unique properties beyond glucose regulation